AAminove
Back to library

Survodutide

Human observational

Also known as: BI 456906

GLP-1 / incretinWeight management (investigational)MASH/liver (investigational)

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

An investigational GLP-1/glucagon dual agonist in phase 3 development for obesity and liver disease. Not yet approved.

Mechanism

Co-activates GLP-1 and glucagon receptors for appetite reduction and increased energy expenditure.

Evidence

Human observationalWhat does this mean?

Phase 2 data reported; phase 3 ongoing. Investigational, not approved.

Community-reported information

Investigational and unapproved outside trials.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~week (once-weekly dosing in trials).

Storage

Refrigerate per trial protocols.

Commonly reported side effects

  • Nausea
  • Vomiting
  • Diarrhoea

Legal status by region

  • USInvestigational; not FDA-approved.

Legal status changes over time; verify locally before relying on this.

Citations